慢性肝病患者肝外并发症死亡率趋势:2007至2017年
该研究基于美国人口普查与国家卫生统计中心2007至2017年死亡记录,分析病毒性肝炎、酒精性肝病(ALD)及非酒精性脂肪性肝病的肝外并发症死亡率趋势。结果显示,丙型肝炎病毒(HCV)感染者肝外癌症年龄标准化死亡率为2.6%、心血管病为1.9%、糖尿病为3.3%;乙型肝炎病毒感染者肝外并发症年龄标准化死亡率年均增加2.0%;非酒精性脂肪性肝病患者最常见死因为心血管病且逐渐上升,而肝病相关死亡率快速增加。
要点
- HCV感染者肝外癌症年龄标准化死亡率为2.6%,心血管病为1.9%,糖尿病为3.3%。
- HBV感染者肝外并发症年龄标准化死亡率年均增加2.0%。
- NAFLD患者最常见死因为心血管病,研究期间逐渐上升,肝病相关死亡率快速增加。
核心结论
- 广泛使用直接抗病毒药物(DAA)治疗病毒性肝炎后,肝外癌症的病因特异性死亡率增加,而心血管病或糖尿病死亡率仅在HCV感染者中增加。
- 研究结果提示需要重新评估经DAA成功治疗的HCV感染者的肝外癌症、心血管病和糖尿病风险及危险因素。
研究设计与样本
- 基于美国人口普查和国家卫生统计中心2007至2017年死亡记录的人群研究。
- 采用Joinpoint趋势分析估算年龄标准化死亡率的年度百分比变化。
主要发现
- HCV感染者肝病相关死亡率从2007年至2013年增加,自2014年至2017年患者开始接受DAA治疗后下降。
- HCV感染者肝外癌症年龄标准化死亡率为2.6%,心血管病为1.9%,糖尿病为3.3%。
- HBV感染者肝病相关死亡率从2007年至2017年稳步下降,而肝外并发症年龄标准化死亡率年均增加2.0%。
- ALD肝病相关死亡率持续增加,但肝外并发症死亡率在11年研究期间无显著变化。
- NAFLD患者最常见死因为心血管病,研究期间逐渐增加,而肝病相关死亡率快速增加。
关键数值与推荐
- HCV感染者肝外癌症年龄标准化死亡率为2.6%。
- HCV感染者心血管病年龄标准化死亡率为1.9%。
- HCV感染者糖尿病年龄标准化死亡率为3.3%。
- HBV感染者肝外并发症年龄标准化死亡率年均增加2.0%。
临床怎么用
- 研究结果提示需重新评估经DAA成功治疗的HCV感染者的肝外癌症、心血管病和糖尿病风险及危险因素。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Trends of mortality associated with extrahepatic complications of chronic liver disease might be changing. We studied trends in mortality from extrahepatic complications of viral hepatitis, alcoholic liver disease (ALD), and nonalcoholic fatty liver disease in the United States. METHODS: We performed a population-based study using US Census and the National Center for Health Statistics mortality records from 2007 through 2017. We identified trends in age-standardized mortality using Joinpoint trend analysis with estimates of annual percent change. RESULTS: The liver-related mortality among patients with hepatitis C virus (HCV) infection increased from 2007 through 2013 and then decreased once patients began receiving treatment with direct-acting antiviral (DAA) agents, from 2014 through 2017. Among patients with HCV infection, the age-standardized mortality for extrahepatic cancers was 2.6%, for cardiovascular disease was 1.9%, and for diabetes was 3.3%. Among individuals with hepatitis B virus infection, liver-related mortality decreased steadily from 2007 through 2017. During the study, age-standardized mortality from hepatitis B virus-related extrahepatic complications increased by an average of 2.0% each year. Although liver-related mortality from ALD continued to increase, mortality from extrahepatic complications of ALD did not change significantly during the 11-year study. Among patients with nonalcoholic fatty liver disease, the cause of death was most frequently cardiovascular disease, which increased gradually over the study period, whereas liver-related mortality increased rapidly. CONCLUSIONS: In an analysis of US Census and the National Center for Health Statistics mortality records, we found that after widespread use of DAA agents for treatment of viral hepatitis, cause-specific mortality from extrahepatic cancers increased, whereas mortality from cardiovascular disease or diabetes increased only among patients with HCV infection. These findings indicate the need to reassess risk and risk factors for extrahepatic cancer, cardiovascular disease, and diabetes in individuals successfully treated for HCV infection with DAA agents.
引用
- Kim D, Adejumo AC, Yoo ER, et al. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology. 2019. PMID: 31251928. doi:10.1053/j.gastro.2019.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。